**Claims**

1. A combination of AZD5305, or a pharmaceutically acceptable salt thereof, and abiraterone acetate for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said AZD5305, or a pharmaceutically acceptable salt thereof, and ii) abiraterone acetate to said subject.

2. The combination for use according to claim 1, wherein said treatment also comprises the separate, sequential or simultaneous administration of prednisone or prednisolone.

3. The combination for use according to either claim 1 or claim 2, wherein the metastatic prostate cancer is metastatic hormone sensitive prostate cancer (mHSPC) or metastatic castrate resistant prostate cancer (mCRPC).

4. Use of AZD5305, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said AZD5305, or a pharmaceutically acceptable salt thereof, and ii) abiraterone acetate to said subject.

5. Use of abiraterone acetate in the manufacture of medicament for the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said abiraterone acetate, and ii) AZD5305, or a pharmaceutically acceptable salt thereof, to said subject.

6. The use according to claim 4 or 5, wherein said treatment also comprises the separate, sequential or simultaneous administration of prednisone or prednisolone.

7. The use according to any one of claims 4 to 6, wherein the metastatic prostate cancer is metastatic hormone sensitive prostate cancer (mHSPC) or metastatic castrate resistant prostate cancer (mCRPC).

8. The combination for use according to any one of claims 1 to 3 or the use according to any one of claims 4 to 7, wherein AZD5305 is to be administered once daily.

9. The combination for use or the use according to claim 8, wherein AZD5305 is to be administered in a dose of up to 60 mg per day.

10. The combination for use or the use according to claim 9, wherein AZD5305 is to be administered in a dose of 60 mg per day.

11. The combination for use according to any one of claims 1 to 3 and 8 to 10, or the use according to any one of claims 4 to 10, wherein abiraterone acetate thereof is to be administered once daily.

12. The combination for use or the use according to claim 11, wherein abiraterone acetate is to be administered in a dose of 1000 mg once daily.

13. The combination for use according to any one of claims 1 to 3 and 8 to 12 or the use according to anyone of claims 4 to 12, wherein AZD5305 and abiraterone acetate are to be taken together on an empty stomach, with no food two hours before.

14. A pharmaceutical product comprising i) AZD5305 or a pharmaceutically acceptable salt thereof, and ii) abiraterone acetate.

15. A kit comprising: a first pharmaceutical composition comprising AZD5305, or a pharmaceutically acceptable salt thereof; a second pharmaceutical composition comprising abiraterone acetate; and instructions for using the first and second pharmaceutical compositions in combination.